PRGO Stock Analysis: Perrigo | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 2.089m USD | 12M Return: -29.6% | IE00BGH1M568 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 36.6M
EPS Trend: 14.9%
Qual. Beats: 1
Rev. Trend: -97.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Perrigo Company plc (NYSE: PRGO) is an Ireland-based, Dublin-headquartered provider of over-the-counter (OTC) consumer health and wellness products, operating since 1887 and listed on the NYSE since 1991. The company is organized into two segments-Consumer Self-Care Americas and Consumer Self-Care International-and offers a broad self-care portfolio spanning upper respiratory, infant nutrition and oral electrolytes, digestive health, pain and sleep aids, oral care, smoking cessation, dermatological and skin care, womens health (including contraceptives), and vitamins, minerals, and supplements. Its products are sold under numerous owned and licensed brands such as Compeed, Mederma, Opill, Prevacid24HR, REACH, Rembrandt, NiQuitin, ACO, and ellaOne, and it also provides contract manufacturing services to third parties. Distribution reaches consumers through retail drug chains, supermarkets, mass merchandisers, e-commerce, wholesalers, pharmacies, and para-pharmacies.
Within the Health Care sector (GICS Sub Industry: Pharmaceuticals), Perrigo sits in the consumer healthcare/OTC subsegment rather than the prescription drug industry, which typically relies on patent-protected branded or biologic molecules sold to physicians and insurers. Instead, Perrigos business model centers on store-brand and value-tier OTC health products, where revenue is driven by retail shelf placement, brand licensing, and private-label contracts with major grocers and drug chains rather than by drug development pipelines.
- Opill OTC contraceptive launch drives US segment revenue growth
- European OTC pricing pressure compresses international segment margins
- Private label competition erodes US store brand OTC market share
| Net Income: -1.73b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.24 > 1.0 |
| NWC/Revenue: 33.70% < 20% (prev 34.42%; Δ -0.72% < -1%) |
| CFO/TA 0.03 > 3% & CFO 251.8m > Net Income -1.73b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (139.6m) vs 12m ago 1.01% < -2% |
| Gross Margin: 33.26% > 18% (prev 35.73%; Δ -2.46% > 0.5%) |
| Asset Turnover: 46.83% > 50% (prev 42.86%; Δ 3.97% > 0%) |
| Interest Coverage Ratio: -9.11 > 6 (EBIT TTM -1.49b / Interest Expense TTM 163.1m) |
| A: 0.18 (Total Current Assets 2.45b - Total Current Liabilities 1.05b) / Total Assets 7.61b |
| B: -0.53 (Retained Earnings -4.00b / Total Assets 7.61b) |
| C: -0.17 (EBIT TTM -1.49b / Avg Total Assets 8.85b) |
| D: 0.49 (Book Value of Equity 2.52b / Total Liabilities 5.09b) |
| Altman-Z'' = -1.12 = CCC |
| DSRI: 1.12 (Receivables 761.2m/706.6m, Revenue 4.14b/4.33b) |
| GMI: 1.07 (GM 35.73% / 33.26%) |
| AQI: 0.90 (AQ_t 0.57 / AQ_t-1 0.63) |
| SGI: 0.96 (Revenue 4.14b / 4.33b) |
| TATA: -0.26 (NI -1.73b - CFO 251.8m) / TA 7.61b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of October 04, 2026, the stock is trading at USD 14.26 with a total of 2,168,941 shares traded. Over the past week, the price has changed by -7.52%, over one month by -1.59%, over three months by +32.07% and over the past year by -29.55%.
Current recommended Stop Loss: 13.30 (which is 6.7% or 1.5 ATR below the current price).
Perrigo has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold PRGO.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.5 | 15.7% |
P/E Forward = 5.9666
P/S = 0.5041
P/B = 0.7634
P/EG = 1.1418
Revenue TTM = 4.14b USD
EBIT TTM = -1.49b USD
EBITDA TTM = -1.35b USD
Long Term Debt = 3.28b USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last quarter)
Debt = 3.47b USD (from shortLongTermDebtTotal, last quarter) + Leases 173.0m
Net Debt = 3.07b USD (calculated: Debt 3.47b - CCE 399.7m)
Enterprise Value = 5.16b USD (2.09b + Debt 3.47b - CCE 399.7m)
Interest Coverage Ratio = -9.11 (Ebit TTM -1.49b / Interest Expense TTM 163.1m)
EV/FCF = 29.47x (Enterprise Value 5.16b / FCF TTM 175.0m)
FCF Yield = 3.39% (FCF TTM 175.0m / Enterprise Value 5.16b)
FCF Margin = 4.22% (FCF TTM 175.0m / Revenue TTM 4.14b)
Net Margin = -41.85% (Net Income TTM -1.73b / Revenue TTM 4.14b)
Gross Margin = 33.26% ((Revenue TTM 4.14b - Cost of Revenue TTM 2.77b) / Revenue TTM)
Gross Margin QoQ = 30.69% (prev 33.58%)
Tobins Q-Ratio = 0.68 (Enterprise Value 5.16b / Total Assets 7.61b)
Interest Expense / Debt = 4.70% (Interest Expense 163.1m / Debt 3.47b)
Taxrate = 16.03% (16.9m / 105.4m)
NOPAT = -1.25b (EBIT -1.49b * (1 - 16.03%)) [loss with tax shield]
Current Ratio = 2.32 (Total Current Assets 2.45b / Total Current Liabilities 1.05b)
Debt / Equity = 1.38 (Debt 3.47b / totalStockholderEquity, last quarter 2.52b)
Debt / EBITDA = -2.28 (negative EBITDA) (Net Debt 3.07b / EBITDA -1.35b)
Debt / FCF = 17.53 (Net Debt 3.07b / FCF TTM 175.0m)
Total Stockholder Equity = 3.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.60% (Net Income -1.73b / Total Assets 7.61b)
RoE = -55.97% (Net Income TTM -1.73b / Total Stockholder Equity 3.10b)
RoCE = -23.29% (EBIT -1.49b / Capital Employed (Equity 3.10b + L.T.Debt 3.28b))
RoIC = -19.63% (negative operating profit) (NOPAT -1.25b / Invested Capital 6.36b)
WACC = 6.06% (E(2.09b)/V(5.56b) * Re(9.56%) + D(3.47b)/V(5.56b) * Rd(4.70%) * (1-Tc(0.16)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.24 | Cagr: 0.64%
[DCF] Terminal Value 73.10% ; FCFF base≈207.7m ; Y1≈182.1m ; Y5≈147.1m
[DCF] Fair Price = N/A (negative equity: EV 2.36b - Net Debt 3.07b = -706.2m; debt exceeds intrinsic value)
EPS Correlation: 14.91 | EPS CAGR: 1.33% | SUE: 0.84 | # QB: 1
Revenue Correlation: -97.60 | Revenue CAGR: -4.04% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.53 | Chg30d=-6.27% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=2.19 | Chg30d=+3.81% | Revisions=+57% | GrowthEPS=-20.4% | GrowthRev=-4.5%
EPS next Year (2027-12-31): EPS=2.40 | Chg30d=+1.54% | Revisions=+57% | GrowthEPS=+9.6% | GrowthRev=+0.7%
[Analyst] Revisions Ratio: +36% (up=8, down=3)